Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Squamous Cell Cancer: early-phase trial registry
2 of 4 indexed Squamous Cell Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Squamous Cell Cancer: 4 US clinical trials tracked, 2 recruiting.
Squamous Cell Cancer is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Anandasabapathy, Sharmila, M.D., running 1 of these trials.
Enrollment posture brief
Registry condition squamous-cell-cancer
OPEN 2 | RECR 50% | LATE 0 | EARLY 3 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Squamous Cell Cancer lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Squamous Cell Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Squamous Cell Cancer is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Udai Kammula
NCT03935893
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
Rise Therapeutics
NCT06398418
Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer
Anandasabapathy, Sharmila, M.D.
NCT01384708
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
Icahn School of Medicine at Mount Sinai
NCT01358097
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Squamous Cell Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Squamous Cell Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Squamous Cell Cancer page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Squamous Cell Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Anandasabapathy, Sharmila, M.D. sponsors the most Squamous Cell Cancer trials on record, review their full trial history before evaluating a specific study. See Anandasabapathy, Sharmila, M.D.'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Squamous Cell Cancer condition card totals 4 registered trials; most-linked intervention proflavine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.